email article
Patients diagnosed with idiopathic hypersomnia characterized by excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia appeared to benefit from a novel oxybate treatment with 92% less sodium than sodium oxybate (Xyrem), a researcher reported.
Significant worsening was observed in Epworth Sleepiness Scale (ESS) scores for patients receiving placebo compared with lower-sodium oxybate (Xywav), for a mean difference of -6.51 (95% CI -7.99 to -5.03,
P
email article
The investigational agent evobrutinib significantly reduced serum levels of neurofilament light chain (NfL) in patients with relapsing multiple sclerosis (MS), a post hoc analysis of a phase II trial showed.
Treatment with the highly selective Bruton s tyrosine kinase inhibitor (BTK), which targets B cells and myeloid cells, at a dose of 75 mg twice daily resulted in a 16.8% decline in blood NfL levels versus no decline in patients assigned to placebo (
P
email article
More patients with myasthenia gravis who were treated with the investigational agent efgartigimod achieved a sustained improvement in a scale of activities of daily living compared with patients who were given placebo, a researcher reported.
Of patients with generalized myasthenia gravis and anti-acetylcholine receptor antibody (AChR-Ab) positivity in a phase III study, 67.7% receiving efgartigimod achieved at least a 2-point improvement in their Myasthenia Gravis-Activities of Daily Living (MG-ADL) score after the first cycle of treatment, compared with 29.7% of those receiving placebo (
P
email article
Hospitalized COVID-19 patients with acute neurologic syndromes and signs had a much higher risk of death, the Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID) study showed.
Mortality was nearly six times higher in hospitalized COVID-19 patients with clinically verified neurologic manifestations than in hospitalized COVID-19 patients with or without neurologic features (OR 5.99, 95% CI 4.33-8.28,
P